|
From Collegiate Presswire's RadioWire (https://www.cpwire.com/radio): Radio Researchers unveiled long-term study results this week on Fuzeon, the first and only fusion inhibitor for the treatment of HIV. Doctor Corklin Steinhart, a leading HIV researcher, helped conduct the research:
�The new data is very exciting because it extends the durability of Fuzeon to almost one year.�
Fuzeon is effective in patients who have developed resistance to other HIV drugs. Patients like John, who has been living with HIV for 20 years:
�Since I�ve been on Fuzeon, over a year, for the first time in 20 years my virus is undetectable.�
Patients may still develop resistance to Fuzeon. Fuzeon is administered by patients as an injection under the skin twice a day, always in combination with other HIV therapies. Injection sites reactions occur in the majority of patients taking Fuzeon. For more information visit fuzeon-dot-com.
CLICK HERE to download a transcript of this story: CLICK HERE to download a multimedia (MP3) file of this story: © Copyright 2003 Collegiate Presswire, Inc. and NBN/CP RadioWire |